



AnaptysBio

*Leader in SHM for
Antibody Therapeutics*

FOR IMMEDIATE RELEASE

November 10, 2010

**AnaptysBio Adds Dr. Jan de Vries, Dr. Nicholas Lydon
and Dr. Phillip Patten to Advisory Boards**

*Recognized Experts in Drug Discovery and Development, Antibody Generation
and Protein Engineering to Advise Therapeutic Antibody Platform Company*

SAN DIEGO, Calif. – Three additional world-renowned scientists have been named to the scientific and therapeutic advisory boards of [AnaptysBio, Inc.](http://www.anaptysbio.com), a privately-held therapeutic antibody platform and product company: Jan de Vries, Ph.D., Nicholas B. Lydon, Ph.D. and Phillip A. Patten, Ph.D.

“The new advisory board members will provide exceptional expertise for helping establish SHM-XEL™ as the platform of choice for antibody discovery and optimization and building our internal pipeline of novel antibody therapeutics,” said Tom Smart, chairman and CEO of AnaptysBio. “Their contributions are expected to build upon the ongoing input by our founding scientific advisors, whose fundamental insights in B-cell immunology and understanding the mechanism of somatic hypermutation (SHM) provided the basis for AnaptysBio’s SHM-XEL™ platform.”

Therapeutic Advisory Board

AnaptysBio’s therapeutic advisory board is primarily involved in advancing the company’s product pipeline, including the identification of potential antibody targets, establishing profiles for product programs and planning development strategies. Its members are de Vries and Lydon.

De Vries is the former head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. Prior to that, he was head of the Novartis Research Institute in Vienna and global head of the Disease Area Autoimmunity, Transplantation and Inflammation. While at Novartis, de Vries led the early development of many drugs that are now on the market or in late-stage clinical development, including Elidel® for the treatment of atopic dermatitis, Ilaris® (canakinumab) for the treatment of various chronic inflammatory diseases and diabetes, Gilenia® for the treatment of multiple sclerosis and AIN-457, an IL-17 mab for the treatment of autoimmune diseases. De Vries joined Novartis from the DNAX Research Institute for Molecular Biological Research in Palo Alto, California, where he was director of the Immunology department from 1989-1997. From 1985-1989, he was director of the Schering-Plough Institute for Immunological Research in Lyon, France. He has held various academic positions at the Netherlands Cancer Institute in Amsterdam, where he was head of the Department of Immunology from 1979-1985. De Vries received his Ph.D. in Immunology from the University of Amsterdam and spent two years as a visiting scientist at the University of California, San Diego.

Lydon, who holds his doctorate in biochemistry from University of Dundee, Scotland, is a co-founder and director of AnaptysBio. He previously served as vice president, small molecule drug discovery, at Amgen, Inc. Prior to joining Amgen, he was the founder, CEO and President of Kinetix, Inc., a biotech

company focused on the development of selective Protein Kinase inhibitors. He has extensive international drug discovery experience with Schering-Plough (now Merck) in France and Ciba-Geigy (now Novartis) in Switzerland. In 2009, Lydon won the Lasker-DeBakey Clinical Medical Research Award along with two other scientists for the development of Imatinib, a molecularly-targeted treatment for chronic myeloid leukemia, which converted a fatal cancer into a manageable chronic condition. The work was hailed as groundbreaking in cancer therapy and radically altered the prognosis of CML patients. Lydon's other accolades include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation for his contributions to the discovery and development of Gleevec®.

Scientific Advisory Board

AnaptysBio's scientific advisory board is involved in advancing the company's SHM-XEL™ technology platform and its broad applications in antibody generation and protein engineering.

Newly appointed to the scientific advisory board, Patten currently holds the position of senior research fellow at Pioneer Hi-Bred International, Inc. Previously, he served as senior vice president of biology at Achaogen, Inc., and as vice president of science and technology at Maxygen, where he was a founding scientist and developed the company's gene shuffling technology. He earned his bachelor's degree in biology at the California Institute of Technology and his Ph.D. at Stanford University. He was awarded a Damon Runyon Postdoctoral Fellowship at U.C. Berkeley where he did pioneering work on the structural basis of antibody affinity maturation.

Patten joins two founding members of AnaptysBio's scientific advisory board:

- Michael Neuberger, Ph.D., currently joint head of the division of protein and nucleic acid chemistry and member of the executive committee, Medical Research Council, Cambridge, England. His major research interests are directed towards understanding the biochemical processes and the physiological pathways by which antibody diversity is created. He is the lead inventor on various granted patents and applications in the field of antibody engineering. Neuberger received his Bachelors degree at Cambridge University and his doctorate at the University of London.
- Matthew Scharff, M.D., a distinguished professor in the departments of cell biology and medicine at the Albert Einstein College of Medicine, and its former chairman, department of cell biology and director of the cancer center. Scharff has devoted most of his research career to studying the production of antibodies by B cells, the role of antibodies in resistance to infection and in causing autoimmunity and the mechanisms responsible for the generation of antibody diversity. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Scharff received his undergraduate education from Brown University and his M.D. from New York University School of Medicine.

About AnaptysBio

Founded in 2005, [AnaptysBio](#), Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-

XEL™ platform couples somatic hypermutation with mammalian cell display and flow cytometry to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired binding and specificity properties for therapeutic applications. AnaptysBio has established broad intellectual property around the use of SHM, and is currently building a pipeline of novel therapeutic antibody product candidates. For more information, visit www.anaptysbio.com.

Contact:

Gable PR – 619-284-1714

Tom Gable

tom@gablepr.com

Cell: 619-251-3881